Biosig Technologies (NASDAQ:STEX) CIO Mitchell Young Williams Sells 263,863 Shares

Key Points

• CIO Mitchell Young Williams sold 263,863 shares on May 1 at an average price of $0.79 for a total of $208,451.77 to cover tax withholding related to the vesting of equity awards.
• The sale reduced his stake by 7.99%, leaving him with 3,037,648 shares valued at about $2.40 million.
• Shares of STEX traded at $1.02 (50-day moving average $1.49) with a market cap of $183.86 million, while analysts are mixed—average rating "Hold" with a $9 target after some firms lowered ratings and Needham cut its price objective from $12 to $9.

Biosig Technologies, Inc. (NASDAQ:STEX - Get Free Report) CIO Mitchell Young Williams sold 263,863 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $0.79, for a total value of $208,451.77. Following the transaction, the executive directly owned 3,037,648 shares of the company's stock, valued at approximately $2,399,741.92. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Biosig Technologies Stock Performance

NASDAQ STEX traded down $0.17 on Monday, reaching $1.02. 1,588,220 shares of the stock traded hands, compared to its average volume of 1,950,089. The stock's fifty day moving average price is $1.49. The company has a market capitalization of $183.86 million, a P/E ratio of -0.11 and a beta of 1.58. Biosig Technologies, Inc. has a 12 month low of $0.70 and a 12 month high of $14.11.

Biosig Technologies (NASDAQ:STEX - Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($8.23) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on STEX shares. Weiss Ratings raised Biosig Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday. Wall Street Zen lowered Biosig Technologies from a "hold" rating to a "strong sell" rating in a research note on Sunday, April 5th. Finally, Needham & Company LLC reduced their price objective on Biosig Technologies from $12.00 to $9.00 and set a "buy" rating for the company in a research note on Thursday, April 9th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $9.00.

Biosig Technologies Company Profile

Biosig Technologies NASDAQ: STEX is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.